STERIS plc (NYSE: STE) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $265.00 price target on the stock.
Pharmaceutical Sterility Testing Market to Drive Revenue to USD 3.79 Billion by 2032 | CAGR 11.58% [Yahoo! Finance]
Brett Girard's Top Picks for November 13, 2024 [BNN Bloomberg (Canada)]
Why Steris (STE) International Revenue Trends Deserve Your Attention [Yahoo! Finance]
STERIS plc (NYSE: STE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.